• 22Apr

    Famed doctor and Sunday Housecall talk show host, Dr. David Samadi says genetic markers for the early detection of prostate cancer can determine aggressiveness of tumors. Studies have shown that a particular protein appears to be directly related to the malignancy of prostate cancer. Dr. Samadi says this is exciting because doctors could distinguish an aggressively growing prostate cancer from a low-risk one, and this could indicate which therapy is best.

    Scientists from the International Cancer Genome Consortium searched databases containing molecular information on numerous prostate cancer cases. This data was used to test whether the tumor cells of any of the known control proteins are significantly more or less pronounced than healthy cells of the same patients. The researchers identified the most striking difference for the protein BAZ2A. Scientists say that this protein is known to impair the viability of cells. When the scientists switched off BAZ2A in metastatic prostate cancer cells, their growth slowed down.

    Studies also revealed that increased levels of BAZ2A boosts the malignant character of prostate cancer cells.

    Systematic studies of deceased men shows that about 30 percent of those in their fifties have latent prostate cancer. Only in a relatively small number of men, the tumor grows aggressive, forms metastases and must be treated.

    Dr. David Samadi says the PSA test is recommended and widely used around the world, that is, the measurement of the concentration of  prostate- specific antigen  in the blood, but the test have remained controversial. But these genetic markers, say Dr. Samadi, could determine malignancy early. If the results can be clinically confirmed, one would finally have the much sought-after marker to distinguish an aggressively growing prostate cancer from a low-risk one.

    Currently, doctor’s heavily rely on PSA testing, but it’s not foolproof. With these tests, indication of a possible cancer is arbitrary. It may well be that a person with a PSA level of 15 ml does not have carcinoma, but one with a value of 3 ml does. In half of the prostate tumors, and even in one third of invasive growing tumors, the PSA concentration is not increased. However, an increase in PSA over a longer period of time is a warning sign and must be closely monitored.

    A board-certified urologist, Dr. David Samadi has been treating urological diseases for over two decades. He attended Stony Brook University, earning his bachelor’s and medical degree, and then performed his residency at Montifiore Hospital, in the Bronx, New York. Dr. Samadi also was a fellow in oncology at Memorial Sloan Kettering Cancer Center.

    He’s been honored with more than 30 awards, that range from everything like Top Doctor, Patient’s Choice, and New York Metro’s Top Doctor, to being honored with the Community Partner Award, from the American Cancer Society, and two Castle Connolly Awards. Dr. Samadi is recognized for his expertise and achievements, all of the world, as well as being a sought-after surgeon, due to his specialty in minimally invasive surgery.

    Dr. David Samadi’s Social Media: www.youtube.com/user/RoboticOncology



Single Links